Stochastic cost-effectiveness analysis on population benefits

被引:0
|
作者
Chen, Ermo [1 ]
机构
[1] Peking Univ, Sch Math Sci, 5 Yiheyuan Rd, Beijing 100871, Peoples R China
关键词
Stochastic cost-effectiveness analysis; Population benefits; Risk allocation; Return on risk; EFFECTIVENESS ACCEPTABILITY CURVES;
D O I
10.1186/s12962-023-00488-y
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Dealing with randomness is a crucial aspect that cost-effectiveness analysis (CEA) tools need to address, but existing stochastic CEA tools have rarely examined risk and return from the perspective of population benefits, concerning the benefits of a group of individuals but not just a typical one. This paper proposes a stochastic CEA tool that supports medical decision-making from the perspective of population benefits of risk and return, the risk-adjusted incremental cost-effectiveness ratio (ICER). The tool has a traditional form of ICER but uses the cost under a risk-adjusted expectation. Theoretically, we prove that the tool can provide medical decisions trimming that promote the risk-return level on population benefits within any intervention structure and can also serve as a criterion for the optimal intervention structure. Numerical simulations within a framework of mean-variance support the conclusions in this paper. The typical assumption in classical CEA that all get the new intervention versus standard of care may not be the best to achieve the best outcome to population, a mixed structure can be betterThe intervention structure should be modified using a criterion considering slight changes on the structure of the treatment mix.Use a risk adjustment concerning cost and outcome uncertainties in taking expectation in ICER calculation gives the optimal treatment mix for population benefits.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] HEALTH BENEFITS AND COST-EFFECTIVENESS ANALYSIS OF EARLY BREAST CANCER DIAGNOSIS IN BULGARIA
    Slavchev, G.
    Dacheva, A.
    Vutova, Y.
    Djambazov, S.
    VALUE IN HEALTH, 2023, 26 (12) : S124 - S124
  • [42] Health and economic benefits of nucleoside analogue therapy in Australia: a cost-effectiveness analysis
    Seaman, Christopher
    Xiao, Yinzong
    Howell, Jessica
    Scott, Nick
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 78 - 78
  • [43] AMTRAK - COST-EFFECTIVENESS ANALYSIS
    MULVEY, FP
    TRANSPORTATION RESEARCH PART A-POLICY AND PRACTICE, 1979, 13 (05) : 329 - 344
  • [44] WHAT IS COST-EFFECTIVENESS ANALYSIS
    EVANS, DB
    MEDICAL JOURNAL OF AUSTRALIA, 1990, 153 : S7 - S9
  • [45] ANALYSIS OF THE COST-EFFECTIVENESS OF PACS
    HILSENRATH, PE
    SMITH, WL
    BERBAUM, KS
    FRANKEN, EA
    OWEN, DA
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1991, 156 (01) : 177 - 180
  • [46] THE ANATOMY OF COST-EFFECTIVENESS ANALYSIS
    PETERSON, RD
    EVALUATION REVIEW, 1986, 10 (01) : 29 - 44
  • [47] Medicare and cost-effectiveness analysis
    Neumann, PJ
    Rosen, AB
    Weinstein, MC
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (14): : 1516 - 1522
  • [48] DECISION AND COST-EFFECTIVENESS ANALYSIS
    MARLEY, DS
    JOURNAL OF FAMILY PRACTICE, 1990, 30 (02): : 233 - &
  • [49] COST-EFFECTIVENESS ANALYSIS - A REVIEW
    RUTIGLIANO, MJ
    NEUROSURGERY, 1995, 37 (03) : 436 - 443
  • [50] THE ROAD TO COST-EFFECTIVENESS ANALYSIS
    KLARMAN, HE
    MILBANK MEMORIAL FUND QUARTERLY-HEALTH AND SOCIETY, 1982, 60 (04): : 585 - 603